422 related articles for article (PubMed ID: 18472187)
1. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities.
Bydal P; Luu-The V; Labrie F; Poirier D
Eur J Med Chem; 2009 Feb; 44(2):632-44. PubMed ID: 18472187
[TBL] [Abstract][Full Text] [Related]
2. 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines.
Ngatcha BT; Laplante Y; Labrie F; Luu-The V; Poirier D
Mol Cell Endocrinol; 2006 Mar; 248(1-2):225-32. PubMed ID: 16359782
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships.
Bydal P; Auger S; Poirier D
Steroids; 2004 May; 69(5):325-42. PubMed ID: 15219411
[TBL] [Abstract][Full Text] [Related]
4. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Laplante Y; Cadot C; Fournier MA; Poirier D
Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and preliminary evaluation of a modified estradiol-core bearing a fused γ-lactone as non-estrogenic inhibitor of 17β-hydroxysteroid dehydrogenase type 1.
Ouellet E; Ayan D; Poirier D
Bioorg Med Chem Lett; 2011 Sep; 21(18):5510-3. PubMed ID: 21782424
[TBL] [Abstract][Full Text] [Related]
6. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
7. Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Maltais R; Fournier MA; Poirier D
Bioorg Med Chem; 2011 Aug; 19(15):4652-68. PubMed ID: 21741247
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase.
Poirier D; Bydal P; Tremblay MR; Sam KM; Luu-The V
Mol Cell Endocrinol; 2001 Jan; 171(1-2):119-28. PubMed ID: 11165020
[TBL] [Abstract][Full Text] [Related]
9. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
11. N-Butyl-N-methyl-11-(3'-hydroxy-21', 17'-carbolactone-19'-nor-17'alpha-pregna-1',3', 5'(10')-trien-7'alpha-yl)-undecanamide: an inhibitor of type 2 17beta-hydroxysteroid dehydrogenase that does not have oestrogenic or androgenic activity.
Sam K; Labrie F; Poirier D
Eur J Med Chem; 2000 Feb; 35(2):217-25. PubMed ID: 10758283
[TBL] [Abstract][Full Text] [Related]
12. Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship.
Tchédam Ngatcha B; Luu-The V; Labrie F; Poirier D
J Med Chem; 2005 Aug; 48(16):5257-68. PubMed ID: 16078844
[TBL] [Abstract][Full Text] [Related]
13. The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals.
Nashev LG; Schuster D; Laggner C; Sodha S; Langer T; Wolber G; Odermatt A
Biochem Pharmacol; 2010 Apr; 79(8):1189-99. PubMed ID: 20005209
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities.
Tremblay MR; Luu-The V; Leblanc G; Noël P; Breton E; Labrie F; Poirier D
Bioorg Med Chem; 1999 Jun; 7(6):1013-23. PubMed ID: 10428369
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.
Watanabe K; Kakefuda A; Yasuda M; Enjo K; Kikuchi A; Furutani T; Naritomi Y; Otsuka Y; Okada M; Ohta M
Bioorg Med Chem; 2013 Sep; 21(17):5261-70. PubMed ID: 23845281
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
Marchais-Oberwinkler S; Frotscher M; Ziegler E; Werth R; Kruchten P; Messinger J; Thole H; Hartmann RW
Mol Cell Endocrinol; 2009 Mar; 301(1-2):205-11. PubMed ID: 18950679
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
[TBL] [Abstract][Full Text] [Related]
18. Selectivity and potency of the retroprogesterone dydrogesterone in vitro.
Rižner TL; Brožič P; Doucette C; Turek-Etienne T; Müller-Vieira U; Sonneveld E; van der Burg B; Böcker C; Husen B
Steroids; 2011 May; 76(6):607-15. PubMed ID: 21376746
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
[TBL] [Abstract][Full Text] [Related]
20. Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
Schuster D; Nashev LG; Kirchmair J; Laggner C; Wolber G; Langer T; Odermatt A
J Med Chem; 2008 Jul; 51(14):4188-99. PubMed ID: 18533708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
